Axsome Therapeutics 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Axsome Therapeutics reported third-quarter 2026 total revenue of $259.7 million, up 52% year-over-year and 19% sequentially, with the commercial portfolio exceeding a $1 billion annual run rate.
- Alvelity net product sales were $207.6 million, up 53% year-over-year and more than 15% sequentially; Sunosi net product revenue was $48.2 million, up 47% year-over-year; and Symbravo net product sales were $3.9 million, up 88% year-over-year.
- Total prescriptions for Alvelity reached approximately 302,000, up 40% year-over-year and 14% sequentially, compared with antidepressant market growth of 3% and 2%, respectively.
- For Alvelity patients 65 years and older, new-to-brand prescriptions grew 211% year-over-year and 99% sequentially, while total prescriptions grew 101% year-over-year and 43% sequentially; for patients under 65, new-to-brand prescriptions grew 27% year-over-year and 10% sequentially, while total prescriptions grew 33% year-over-year and 10% sequentially.
- Axsome activated approximately 8,200 new Alvelity prescribers in the quarter, up 49% from the prior quarter, bringing the total number of unique prescribers since launch to approximately 77,000; primary care represented nearly 40% of prescribers and 25% of prescriptions.
- Symbravo prescriptions exceeded 25,000, up 382% year-over-year and 7% sequentially, compared with migraine market growth of 6% and 4%, respectively; Sunosi prescriptions exceeded 64,400, up 15% year-over-year and 6% sequentially.
- Research and development expenses were $50.6 million, selling, general and administrative expenses were $203.1 million, and cost of revenue was $17.8 million; gross margin remained in the low to mid-90% range.
- Net loss was $12.9 million, or 25 cents per share, compared with $47.2 million, or 94 cents per share, in the third quarter of 2025; the quarter's net loss included $26.4 million in stock-based compensation expense.
- Axsome ended the quarter with approximately $314 million in cash and cash equivalents, compared with $323 million at year-end 2025.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, and welcome to the Axsome Therapeutics Third Quarter 2026 Earnings Conference Call. My name is Kevin. I'll be your operator for today's call. At this time, all participants are in listen-only mode. Later, we'll conduct a question-and-answer session. Instructions will be given at that time. Please note, this call is being recorded. I will now turn the call over to Ashley Dong, Senior Director of Investor Relations. Ashley, please go ahead. Thank you.
Good morning, everyone. Welcome to Axsome's Third Quarter 2026 Earnings Conference Call. Joining me today are Dr. Herriot Tabuteau, Chief Executive Officer, Nick Pizzie, Chief Financial Officer, and Ari Maizel, Chief Commercial Officer, who will begin with prepared remarks. Mark Jacobson, our Chief Operating Officer, and Hunter Murdock, our General Counsel, will also be available for Q&A. Before we begin, I encourage everyone to visit the Investors section of our website to find the press release and presentation for today's call. Please note that today's discussion includes forward-looking statements regarding our financial performance, commercial strategy, and operational plans, including research, development, and regulatory activities. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that may cause actual results to differ materially. Please refer to our SEC filings, including our quarterly and annual reports, for a description of these and other risks.
You are cautioned not to rely on these forward-looking statements, which are made only as of today, and the company disclaims any obligation to update such statements. With that, I'll hand it over to Herriot.
Thank you, Ashley, and good morning, everyone. Axsome delivered another robust quarter across our business, driven by continued commercial progress and advancements in our industry-leading neuroscience pipeline. Our commercial portfolio generated $260 million in total revenue in the quarter, representing growth of 52% year-over-year, surpassing a $1 billion annual run rate. We expect sustained momentum for AUVELITY, driven by strong underlying demand growth in major depressive disorder and continued acceleration of new patient initiations in Alzheimer's disease agitation. SUNOSI continues to show persistent and steady growth. For SYMBRAVO, our expanded sales team is driving important trial and adoption. Nick will discuss our financials for the quarter, followed by Ari, who will comment on our commercial business.
In parallel with the commercial portfolio, our industry-leading neuroscience pipeline comprises 10 development programs, including significant label expansion opportunities for AUVELITY and SUNOSI, as well as novel product candidates with potential first-in-class and best-in-class profiles across areas of high unmet need in brain health. I will review our recent pipeline progress later in the call. Overall, our commercial portfolio is growing, and our industry-leading R&D portfolio is well-positioned to potentially deliver multiple waves of innovation to patients. I will now turn the call over to Nick to review our financials.
Thanks, Ariho, and good morning, everyone. Total revenue reached $259.7 million in the third quarter, representing accelerated growth of 52% year-over-year and 19% sequentially. AUVELITY net product sales were $207.6 million, representing 53% year-over-year growth and an increase of over 15% sequential growth. Sequential increases over the past two quarters more than doubled the average quarterly increase prior to the label expansion in Alzheimer's disease agitation. SUNOSI net product revenue was $48.2 million in the third quarter, representing 47% year-over-year growth. This consisted of $38.5 million in net product sales, $1.2 million in royalty revenue associated with sales in out-licensed territories, and $8.5 million in milestone revenue recorded related to cumulative ex-U.S. net revenue. SYMBRAVO net product sales were $3.9 million in the quarter, representing 88% year-over-year growth. The gross-to-net discount for SYMBRAVO was in the mid-80% range.
Gross-to-net discounts for AUVELITY improved to the mid-to-high 40% range. SUNOSI also improved into the high 40% range for the third quarter. We anticipate gross-to-net discounts for both products to increase slightly in Q4 due to typical seasonality. Turning to expenses, cost of revenue in the quarter was $17.8 million compared to $11.9 million in the third quarter of 2025. Gross margin remained healthy in that low-to-mid 90% range. Research and development expenses were $50.6 million compared to $40.2 million in the third quarter of 2025, primarily reflecting costs associated with our ongoing late-stage clinical programs for solriamfetol, AXS-14, and AXS-05. Selling, general, and administrative expenses were $203.1 million compared with $150.2 million for the third quarter of 2025. The increase versus prior year was primarily driven by commercialization activities for AUVELITY and SYMBRAVO.
SG&A was essentially flat quarter over quarter as the bulk of the original field force expansion is now reflected in our run rate. Finally, net loss for the quarter decreased to $12.9 million, or $0.25 per share, compared with $47.2 million, or $0.94 per share, in the third quarter of 2025. This improvement underscores the continued operating leverage in our business as revenue growth increasingly translates to the bottom line. The net loss of $12.9 million for the quarter included $26.4 million in stock-based compensation expense. Turning to the balance sheet, we ended the quarter with approximately $314 million in cash and cash equivalents. This compares to $323 million at year-end 2025. We continue to expect that our current cash balance will be sufficient to fund anticipated operations through cash flow positivity.
With that, I would like to turn the call over to Ari for a commercial update.
Thanks, Nick, and good morning, everyone. I am pleased to share the progress across our portfolio of 3 approved medicines, particularly the growing momentum behind AUVELITY. Overall, total prescriptions reached approximately 302,000 in the third quarter, an increase of 40% year-over-year and 14% sequentially, significantly outpacing the antidepressant market, which grew 3% and 2% in the same time periods, respectively. In addition, Q3 marked the second consecutive quarter of double-digit demand growth for both new-to-brand prescriptions and total prescriptions across all age groups, with acceleration across both indications. In the 65 years and older segment, which reflects primarily the Alzheimer's agitation indication, new-to-brand prescriptions grew 211% year-over-year and 99% sequentially. New-to-brand prescriptions reflect new patient starts and are a key leading indicator of total prescription growth. In the quarter, total prescriptions in the 65 years and older segment grew 101% year-over-year and 43% sequentially.
In the less than 65-year-old segment, which reflects primarily the major depressive disorder indication, new-to-brand prescriptions grew 27% year-over-year and 10% sequentially. Total prescriptions in the less than 65-year-old segment grew 33% year-over-year and 10% sequentially in the quarter. We expect momentum in new-to-brand prescriptions to continue, contributing to ongoing and increasing total prescription growth in the coming quarters. Overall, AUVELITY growth is being driven by both increased prescribing frequency among existing writers and continued acceleration in new writer activation. In the third quarter, we activated approximately 8,200 new AUVELITY prescribers, representing 49% growth versus the prior quarter and bringing the total number of unique AUVELITY prescribers since launch to approximately 77,000. Our expanded AUVELITY sales team is driving broader adoption across prescriber segments, particularly primary care, which remains the fastest-growing segment for AUVELITY in terms of both prescribers and prescription volume across both indications.
Primary care represented nearly 40% of prescribers and 25% of total prescriptions in the quarter. We expect primary care adoption to continue to grow in MDD and Alzheimer's agitation and remain an important driver of long-term growth for the overall brand. The breadth of AUVELITY demand growth across indications, age cohorts, prescriber segments, and settings of care is a positive signal of the impact AUVELITY is having on patients and prescribers throughout the U.S. We are very pleased with feedback of the clinical responses observed in real-world settings, which include rapid and sustained symptom relief, positive impact on quality of life, and a manageable safety and tolerability profile for both MDD and Alzheimer's disease agitation patients. AUVELITY coverage remains at approximately 89% of total lives across channels, including 82% of commercial lives and approximately 100% of lives in the government channel.
Our market access team is working closely with payers in both the commercial and government channels, and we expect patient access for AUVELITY in both the MDD and Alzheimer's agitation markets to continue to expand and evolve. Based on AUVELITY's initial uptake in Alzheimer's disease agitation and sustained momentum in MDD, AUVELITY is well-positioned to generate at least $8 billion in annual revenue at peak. Turning now to SYMBRAVO, which grew 382% versus Q3 2025 and 7% sequentially to more than 25,000 total prescriptions, outperforming the migraine market, which grew 6% versus Q3 2025 and 4% sequentially. New prescriber growth from the neurology and primary care segments underscores the growing place in treatment for SYMBRAVO for patients who experience inadequate response to prior acute migraine treatment options.
Prescriber and patient feedback consistently highlights SYMBRAVO's rapid impact on migraine symptoms, sustained response out to 24 and 48 hours, and predictability of response across multiple migraine attacks. Overall payer coverage remains at approximately 57% of lives covered across channels, including approximately 56% of commercial lives and 57% of government lives. We expect coverage for SYMBRAVO to expand and evolve moving forward. SUNOSI delivered another quarter of growth, with more than 64,400 total prescriptions written during the quarter, representing 15% year-over-year growth and 6% sequential growth, compared to the wake-promoting agent market, which was flat compared to Q3 2025 and experienced a 2% increase versus the prior quarter. Nearly 17,650 clinicians have now prescribed SUNOSI since launch, and we continue to maintain broad payer coverage of approximately 82% of lives covered across all channels.
With an established commercial infrastructure, robust growth for AUVELITY in MDD and Alzheimer's disease agitation, continued progress for SYMBRAVO in migraine, and durable growth for SUNOSI in EDS associated with narcolepsy and obstructive sleep apnea, Axsome is poised to drive demand across our novel medicines and positively impact patients throughout the U.S. for years to come. I will now turn the call back to Ariel.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
28 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
